
aug pm et
summari lead biotech compani major treatment anemia neutropenia
rheumatoid psoriat arthriti psoriasi cancer osteoporosi
price-to-earnings oper ep
risk assess reflect particip
highli competit regul market subject
chang govern reimburs polici
drug safeti oversight see risk mitig
diversifi product roster gener robust
cash flow support share repurchas cash dividend
new asset acquisit
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug stock trade
see sale modestli
flat sale
expect legaci product face
headwind off-set growth new
product prolia xgeva enbrel
kyproli expect oper margin
cost
sale repatha inhibitor remain
soft
believ recent inclus
cardiovascular outcom data prescrib
inform help sale march
data phase fourier trial show
cardiovascular event base
fourier trial decemb fda
approv repatha first inhibitor
prevent heart attack stroke
aimovig approv may fda
treat migrain encount issu
third parti payer prescript benefit
manag regard price
annual set patient assist
program provid free trial
aimovig negoti payer on-going
believ complet contract
obtain coverag cover
think share trade
ep estim slightli
peer near mid-point
five-year rang near fair
valu concern
matur drug portfolio yet think
robust pipelin compound phase
trial could acceler growth
still sever year away believ
price aimovig low-end expect
price point express script esrx
indic may limit access drug
price high septemb
announc deal regard
humira biosimilar amjevita deal
grant licens humira
intellectu properti licens begin
januari octob
europ
risk recommend target
includ pipelin failur inabl secur
new drug approv inabl obtain
reimburs agreement third-parti
target base
slightli peer forward
ep estim peer
growth due declin sale legaci
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
oper
corpor overview among world largest biotech compani engag discov
develop manufactur deliv human therapeut current market five
world best-sel biotech drug compani strategi develop medicin six focus
therapeut area meet primari unmet medic need address seriou ill compani
presenc approxim countri world-wide primari focu oncology/hematolog
cardiovascular diseas inflamm bone health nephrolog neurosci
major concentr compani sale market forc base europ
addit compani market product part latin america middl east asia
 compani sell primarili pharmaceut wholesal distributor turn sell
product health care provid compani also market certain product directli consum
direct-to-consum print televis advertis well multi-channel market
outsid compani sell princip health care provid and/or pharmaceut wholesal
distributor depend distribut practic countri
compani product sale three major wholesal cardin
account approxim total revenu year end decemb
product enbrel etanercept compani market enbrel primarili medic
use primarili treatment adult patient moder sever activ rheumatoid arthriti
chronic moderate-to-sever plaqu psoriasi patient candid system therapi
phototherapi activ psoriat arthriti right market sell enbrel outsid
canada
neulasta pegfilgrastim compani market neulasta pegyl protein base filgrastim
molecul primarili europ neulasta use primarili help reduc chanc infect
due low white blood cell count peopl certain type cancer non-myeloid receiv
anti-canc medicin chemotherapi caus fever low blood cell count
aranesp darbepoetin alfa compani market aranesp primarili europ aranesp
indic treatment anemia caus chronic kidney diseas ckd patient dialysi
patient dialysi aranesp also indic treatment anemia due concomit
myelosuppress chemotherapi patient non-myeloid malign chemotherapi
would use least two month start aranesp
epogen epoetin alfa compani market epogen dialysi patient compani
market epogen treat lower-than-norm number red blood cell anemia caus ckd
patient dialysi lessen need red blood cell transfus major compani sale
two dialysi provid
sensipar/mimpara cinacalcet compani market cinacalcet sensipar primarili
mimpara primarili europ use primarili treatment secondari hyperparathyroid
adult patient ckd dialysi
xgeva denosumab compani market xgeva primarili europ xgeva use primarili
prevent skeletal-rel event sre patholog fractur radiat bone spinal cord
compress surgeri bone patient bone metastas solid tumor
prolia denosumab compani market prolia primarili europ contain
activ ingredi xgeva approv differ indic patient popul dose
frequenc administr use primarili treatment postmenopaus women
osteoporosi high risk fractur
pipelin juli compound pipelin includ compound phase
trial five compound phase ii trial also signific presenc biosimilar market
five biosimilar develop
major develop may fda approv aimovig novel treatment develop specif
migrain prevent aimovig self-administ monthli devic sureclick
autoinjector requir load dose septemb announc deal
regard humira biosimilar amjevita deal grant licens humira
intellectu properti licens begin januari octob europ
compani announc fda grant approv repatha adjunct diet
maxim toler statin therapi treatment adult heterozyg famili
hypercholesterolemia clinic atherosclerot cardiovascular diseas requir addit lower
ldl-c adjunct diet ldl-lower therapi treatment patient
homozyg famili hypercholesterolemia requir addit lower ldl-c
compani announc european commiss ec grant market author repatha
treatment high cholesterol adjunct diet januari perman patent
infring case regeneron sanofi hypercholesterolemia drug praluent howev
octob court appeal overturn ban praluent sale order
financi trend sale risen billion billion repres
three-year compound annual growth rate compound-annual-growth-rate among highest gross margin
biotech industri gross margin rose significantli aid
new product approv adjust ep rose repres
three-year compound-annual-growth-rate
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc august technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
biotechnolog sub-industri next
month reflect favor prospect new
novel therapi reach commerci yet
anticip modest overal
sale growth mainli due forecast
mid-teen sale declin
biotech sale rose low singl
digit follow growth
follow robust growth period
compound annual growth
rate think sale growth
somewhat limit heighten focu high
drug price encourag view
strong period report
late-stag clinic result
accommod fda approv
fda approv new drug --
sinc record approv
howev fda approv
new drug significantli robust
new drug approv think mani
newly-approv drug signific
commerci prospect repres major
advanc therapi diseas
sclerosi cancer fda
approv first time gene-therapi drug
involv remov patient immun cell
genet alter alter
cell re-introduc patient
help fight cancer
expect wider adopt biomark research
genetic-target clinic studi help
late fda introduc breakthrough
therapi design intend speed
develop promis program expect
favor merger acquisit climat
larg pharmaceut firm move off-set
lost revenu expir drug patent
larg biotech bolster drug pipelin amid
larger scale acquisit
fda author govern biosimilar
drug approv set exclus
advanc modest rate next
sever year see improv
biosimilar approv introduc
march fda approv novarti
filgrastim biosimilar version
novarti began sell
biosimilar name zarxio septemb
april fda approv
inflectra manufactur celltrion
co-market inflectra
biosimilar johnson johnson
expect biosimilar sell modest price
discount gener pharmaceut
industri due higher clinic manufactur
market cost expect brand
drug retain signific market share due
lack interchang think
biosimilar may appeal new user
expect current user stabl
current treatment would like continu
refer drug howev note
prescript benefit manag health
insur exert influenc drug
prescript price
remov neupogen formulari
replac zarxio
 biotech index rose vs
rise year date
juli biotech index
rose vs rise
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep buy opinion share inc
keep target slightli peer
ep estim near high-end rang
ep vs ahead estim sale fell
enbrel sale fell amid increas competit repatha sale
remain soft agmn negoti payer improv access drug
keep sale guidanc rais low end ep guidanc
concern agmn matur drug portfolio
view new drug pipelin posit /jeffrey loo cfa
et capit iq reiter buy opinion share
inc releas posit data
patient fourier trial repatha result show repatha cut overal major
advers cardiovascular event includ heart attack stroke
coronari revascular observ effect
cardiovascular mortal view result posit uncertain
result enough convinc insur reimburs repatha hefti
price effort remov barrier access
offer refund repatha cost patient stroke heart attack
analyst research note compani news
keep target slightli peer
forward ep estim slower-than-p growth ep
vs ahead view aid lower tax rate
lower number share outstand rais ep estim
ep estim sale rose new
product sale -- includ prolia kyproli xgeva
-- partial off-set continu sale declin matur product
best-sel drug enbrel declin neulasta sale flat
aimovig recent approv fda treat migrain encount issu
third-parti payer pharmaci benefit manag regard price
set patient assist program provid free
two-month trial aimovig negoti payer on-going say
complet contract obtain coverag cover live
et cfra keep hold opinion share inc
keep target line peer
ep estim rais ep estim
ep vs ahead view sale rose
new product grow least sale top drug
neulasta fell enbrel fell expect fda approv
migrain drug aimovig next month note express script esrx largest
pharmaci benefit manag pbm indic may limit access drug due
anticip high list price exr suggest
reason gross-to-net price would reduc rebat esrx also
said ask refund drug work within defin time
period expect third parti payer exert pressur drug price
cholesterol drug repatha face similar challeng limit
sale sale grow though still well
et cfra lower opinion share hold buy
lower target line
peer ep estim set
ep vs view sale fell matur
product sale continu fall enbrel sale fell lower demand
sell price neulasta sale flat newer drug solid gain
repatha prolia kyproli rose also see repatha
sale benefit cardiovascular data ad prescrib inform
still see sale fall soft matur product /jeffrey loo
et cfra keep buy opinion share inc
keep target price slightli peer
forward ep estim ep vs
estim rais ep estim
sale fell line forecast newer product
includ prolia blincyto kyproli
matur product line continu declin howev oper margin
improv basi point improv cost control manufactur
effici aid expir enbrel residu royalti payment
et cfra reiter buy opinion share inc
rais target slightli peer
forward ep estim ep vs
ahead estim rais ep estim
sale rose new product sale includ prolia kyproli
partial off-set declin older drug repatha sale increas
still forecast see gradual uptak
narrow sale guidanc
increas ep estim /jeffrey
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share
grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
